This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Coalition to Stop Opioid Overdose | |
|---|---|
| Name | Coalition to Stop Opioid Overdose |
| Formation | 2000s |
| Type | Nonprofit |
| Headquarters | Washington, D.C. |
| Region served | United States |
| Leader title | Executive Director |
Coalition to Stop Opioid Overdose is a U.S.-based nonprofit advocacy organization focused on reducing fatalities from opioid overdose through education, naloxone distribution, policy advocacy, and research translation. The organization operates at the intersection of public health, harm reduction, and law, engaging with a range of stakeholders including healthcare systems, criminal justice agencies, community groups, and international partners. It has worked alongside prominent actors in overdose prevention, public policy, emergency medicine, and addiction treatment to influence practice and legislation.
The Coalition to Stop Opioid Overdose emerged in the early 2000s amid rising attention to opioid-related mortality, coinciding with heightened activity by Centers for Disease Control and Prevention, Substance Abuse and Mental Health Services Administration, National Institutes of Health, Food and Drug Administration, and state public health departments. Founders and early supporters included clinicians from institutions such as Johns Hopkins Hospital, Massachusetts General Hospital, and academics affiliated with Harvard Medical School and University of California, San Francisco. The coalition expanded its network through collaborations with advocacy groups like Harm Reduction Coalition, Drug Policy Alliance, American Public Health Association, and patient organizations such as American Society of Addiction Medicine. Over time it responded to events including the rise of synthetic opioids like fentanyl and policy shifts tied to laws such as the Controlled Substances Act and Good Samaritan statutes enacted in multiple jurisdictions.
The coalition's stated mission emphasizes preventing opioid overdose deaths by increasing access to overdose reversal medications, supporting evidence-based treatment, and reducing stigma. Goals align with public health frameworks advanced by entities such as World Health Organization, Pan American Health Organization, and United Nations Office on Drugs and Crime while resonating with clinical priorities set by professional organizations like American Medical Association, American College of Emergency Physicians, and American Psychiatric Association. Specific objectives include expanding naloxone availability, promoting medication-assisted treatment modalities endorsed by National Institute on Drug Abuse, and influencing legislation analogous to statewide naloxone access laws championed in places like Rhode Island and Massachusetts.
The coalition is organized as a membership network comprised of healthcare providers, academic researchers, harm reduction organizations, faith-based groups, legal advocates, and municipal partners. Member institutions have included hospitals such as Mount Sinai Hospital, universities such as Yale University, community organizations such as Chicago Recovery Alliance, and professional societies like Emergency Nurses Association. Governance typically involves a board of directors, advisory committees with experts from Columbia University, University of Michigan, and Brown University, and working groups aligned with policy, training, and research portfolios. The coalition has engaged local health departments in cities like Seattle, Philadelphia, and Baltimore to implement programs.
Programs have centered on naloxone distribution training, responder education for first responders including Fire Department of New York personnel, and development of clinical toolkits used in emergency departments at institutions such as Cleveland Clinic. Initiatives include community-based overdose prevention projects modeled after programs in Vancouver and Glasgow, pilot collaborations with syringe services programs like those in San Francisco and training modules informed by guidelines from American Heart Association. The coalition has sponsored workshops at conferences hosted by Society for Academic Emergency Medicine and promoted best practices for post-overdose care pathways similar to efforts in Portland, Oregon.
Advocacy efforts have encompassed support for expanded naloxone access, Good Samaritan laws, and insurance coverage for medication-assisted treatment with agents such as buprenorphine and methadone. The coalition has lobbied state legislatures and federal bodies including testimony before committees in the United States Congress and engagement with agencies such as Centers for Medicare and Medicaid Services. It has collaborated with coalitions that successfully advocated for overdose prevention reforms in jurisdictions influenced by campaigns from groups like Shatterproof and Faces & Voices of Recovery. Policy briefs have addressed intersections with criminal justice reform movements linked to organizations such as The Sentencing Project.
The coalition has produced and disseminated white papers, training curricula, and literature reviews drawing on evidence from peer-reviewed journals affiliated with publishers such as JAMA, The Lancet, and New England Journal of Medicine. Research partnerships have included investigators from Brown University School of Public Health, Columbia University Mailman School of Public Health, and Johns Hopkins Bloomberg School of Public Health and have examined naloxone effectiveness, post-overdose linkage to care, and the impact of synthetic opioids documented by surveillance systems operated by National Center for Health Statistics. Publications have been presented at meetings of American Public Health Association, International Society for Pharmacoeconomics and Outcomes Research, and National Harm Reduction Conference.
Funding has been drawn from philanthropic entities, foundations, and institutional grants including foundations modeled on Robert Wood Johnson Foundation, The Rockefeller Foundation, and programmatic collaborations with agencies such as Centers for Disease Control and Prevention and Substance Abuse and Mental Health Services Administration. Partnerships have extended to community health centers, hospital systems like Kaiser Permanente, and international collaborators such as organizations in Canada and United Kingdom public health networks. The coalition has also worked with corporate partners on supply-chain issues while maintaining independence advocated by nonprofit governance standards promoted by Council on Foundations.
The coalition has been credited with contributing to wider naloxone availability, influencing state legislative change, and shaping post-overdose care models replicated in municipalities including New York City, Los Angeles, and Chicago. Evaluations cite reductions in community-level overdose fatalities where comprehensive programs were implemented, paralleling findings from studies in Massachusetts and Rhode Island. Criticism has included debates over harm reduction strategies raised by stakeholders in conservative legislatures, tensions with some law enforcement agencies such as certain state police forces, and discussion in academic forums about unintended consequences debated in journals like Health Affairs and Addiction. Ongoing discourse involves balancing overdose reversal efforts with expanded access to long-term treatment endorsed by bodies like National Academies of Sciences, Engineering, and Medicine.